TREATMENT COMPOSITIONS
Compositions for and methods of treating diseases related to oxidative stress are described.
1 . A composition comprising at least one redox signaling agent (RXN) and a PPAR agonist.
2 . The composition of claim 1 , wherein the PPAR agonist comprises a Free Fatty Acid (FFA).
3 . The composition of claim 1 , wherein the PPAR agonist comprises an eicosanoid.
4 . The composition of claim 1 , wherein the PPAR agonist comprises a thazolidinedione.
5 . The composition of claim 1 , wherein the PPAR agonist comprises a fibrate.
6 . The composition of claim 1 , wherein the PPAR agonist comprises a dual agonist.
7 . The composition of claim 6 , wherein the dual agonist comprises aleglitazar.
8 . The composition of claim 6 , wherein the dual agonist comprises muraglitazar.
9 . The composition of claim 6 , wherein the dual agonist comprises tesaglitazar.
10 . The use of a composition comprising RXN and a PPAR agonist in the treatment of a PPAR-mediated disease.
11 . The use of claim 10 , wherein the PPAR-mediated disease is diabetes mellitus.
12 . The use of claim 11 , wherein the diabetes mellitus is type 1 diabetes.
13 . The use of claim 11 , wherein the diabetes mellitus is type 2 diabetes.
14 . The use of claim 10 , wherein the PPAR-mediated disease is obesity.
15 . The use of claim 10 , wherein the PPAR-mediated disease is cancer.
16 . The use of a composition comprising at least one RXN in the treatment of cancer, comprising a first therapy which activates a PPAR pathway and at least one other agent wherein the at least one other agent does not activate a PPAR pathway.
17 . The use of claim 16 , wherein the at least one other agent comprises radiation.
18 . The use of claim 16 , wherein the at least one other agent comprises a chemotherapeutic agent.
19 . The use of a composition comprising at least one RXN in the treatment of cancer, comprising a first therapy which mobilizes Free Fatty Acids (FFAS) and at least one other agent wherein the at least one other agent does not mobilize FFAs.
20 . The use of claim 19 , wherein the at least one other agent comprises radiation.
21 . A method of treating an oxidative stress related disorder comprising:
administering a composition including at least one species selected from O 2 , H 2 , Cl 2 , OCl − , HOCl, NaOCl, HClO 2 , ClO 2 , HClO 3 , HClO 4 , H 2 O 2 , Na + , Cl − , H + , H − , OH − , O 3 , O 4 * − , 1 O, OH* − , HOCl—O 2 * − , HOCl—O 3 , O 2 * − , HO 2 *, NaCl, HCl, NaOH, water clusters, or a combination thereof to a patient experiencing oxidative stress; and
treating the oxidative stress related disorder.
22 . A method of treating a reduced mitochondrial DNA disorder comprising:
administering a composition including at least one species selected from O 2 , H 2 , Cl 2 , OCl − , HOCl, NaOCl, HClO 2 , ClO 2 , HClO 3 , HClO 4 , H 2 O 2 , Na + , Cl − , H + , H − , OH − , O 3 , O 4 * − , 1 O, OH* − , HOCl—O 2 * − , HOCl—O 3 , O 2 * − , HO 2 *, NaCl, HCl, NaOH, water clusters, or a combination thereof to a patient experiencing the reduced mitochondrial DNA disorder;
increasing mitochondrial DNA density; and
treating the reduced mitochondrial DNA disorder.
23 . The method of claim 22 , wherein the reduced mitochondrial DNA disorder is sacropenia, diabetes, Alzheimer's disease, Parkinson's disease, neurological disease, muscle loss due to aging, obesity, or cardiovascular disorders.